Rebecca E Schweppe

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Venues

Cancer biology & therapy

Molecular cancer research : MCR

Cancers

Oncogene

University of Colorado Anschutz Medical Campus

University of Colorado Health Sciences Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Colorado Anschutz Medical Campus

United States

Professor :: Medicine

Education History

University of Colorado Health Sciences Center

United States

PHD

Publications

Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Madison M Rose, Veronica L Espinoza, Katelyn J Hoff, Laura A Pike, Vibha Sharma, Marie-Claude Hofmann, Aik Choon Tan, Nikita Pozdeyev, Rebecca E Schweppe
BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers 15 (2) (2023)
Eric L Bolf, Thomas C Beadnell, Madison M Rose, Angelo D'Alessandro, Travis Nemkov, Kirk C Hansen, Rebecca E Schweppe
Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells 12 (10) (2023)
Madison M Rose, Veronica L Espinoza, Katelyn J Hoff, Laura A Pike, Vibha Sharma, Marie-Claude Hofmann, Aik Choon Tan, Nikita Pozdeyev, Rebecca E Schweppe
BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers 15 (2) (2023)
Hannah M Hicks, Nikita Pozdeyev, Sharon B Sams, Umarani Pugazhenthi, Elise S Bales, Marie Claude Hofmann, Logan R McKenna, Rebecca E Schweppe
Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2. Molecular cancer research : MCR (2023)
Kelsey W Nassar, Jennifer D Hintzsche, Stacey M Bagby, Veronica Espinoza, Christophe Langouët-Astrié, Carol M Amato, Tugs-Saikhan Chimed, Mayumi Fujita, William Robinson, Aik Choon Tan, Rebecca E Schweppe
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Molecular cancer therapeutics 20 (10) (2021)
Hannah M Hicks, Logan R McKenna, Veronica L Espinoza, Nikita Pozdeyev, Laura A Pike, Sharon B Sams, Daniel LaBarbera, Philip Reigan, Christopher D Raeburn, Rebecca E Schweppe
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Molecular carcinogenesis 60 (3) (2021)
Rebecca E Schweppe, Nikita Pozdeyev, Laura A Pike, Christopher Korch, Qiong Zhou, Sharon B Sams, Vibha Sharma, Umarani Pugazhenthi, Christopher Raeburn, Maria B Albuja-Cruz, Philip Reigan, Daniel V LaBarbera, Iñigo Landa, Jeffrey A Knauf, James A Fagin, Bryan R Haugen
Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Molecular cancer research : MCR 17 (5) (2019)
Iñigo Landa, Nikita Pozdeyev, Christopher Korch, Laura A Marlow, Robert C Smallridge, John A Copland, Ying C Henderson, Stephen Y Lai, Gary L Clayman, Naoyoshi Onoda, Aik Choon Tan, Maria E R Garcia-Rendueles, Jeffrey A Knauf, Bryan R Haugen, James A Fagin, Rebecca E Schweppe
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (10) (2019)
Brittelle E Kessler, Katie M Mishall, Meghan D Kellett, Erin G Clark, Umarani Pugazhenthi, Nikita Pozdeyev, Jihye Kim, Aik Choon Tan, Rebecca E Schweppe
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene 38 (14) (2018)

Rebecca E Schweppe.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Rebecca E Schweppe